Last reviewed · How we verify
A Phase 3, Open-Label, Parallel Group Treatment Concordance Study to Compare Insulin Use and Its Effect on Glycemic Control in Patients With Type 2 Diabetes Mellitus: Two Populations With Different Insulin Treatment Options
A study to compare insulin use and its effect on glucose control and other outcomes in patients with Type 2 diabetes who together with their healthcare provider manage their disease by discussing and agreeing on the diabetes treatment chosen from a selection of available treatment options.
Details
| Lead sponsor | Eli Lilly and Company |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 1019 |
| Start date | 2006-06 |
| Completion | 2008-05 |
Conditions
- Diabetes Mellitus, Type 2
Interventions
- Human Insulin Inhalation Powder
- Insulin
Primary outcomes
- To assess acceptance of insulin therapy — 9 months
- To assess blood sugar control as measured by HbA1c — baseline, 1,3,5,7,9 months
Countries
United States, Argentina, Brazil, Canada, Denmark, India, Mexico, Poland, Puerto Rico, Russia, South Africa, South Korea